160 research outputs found
Recommended from our members
Extended treatment with MY-NEOVAX, personalized neoantigen-enhanced oncolytic viruses, for two end-stage cancer patients.
Neoantigen vaccines involving multi-peptides and poly-epitope-encoding RNA or DNA have undergone early phase clinical testing with modest reported antitumor effects [ 1]. The less-than-expected activity of these neoantigenic vaccines may correspond with the development of immune escape mechanisms. One permutation on neoantigen vaccines, which may counter or prevent these adaptive immune escape mechanisms, are 'personalized' oncolytic viruses that encode one or more tumor-specific transgenes. Herein, positive therapeutic effects for MY-NEOVAXâ„¢, personalized neoantigen-enhanced oncolytic adenoviruses, are described for two heavily pretreated end-stage patients, one with high-grade metastatic neuroendocrine carcinoma of the pancreas and the other with colorectal cancer metastatic to the brain, liver and lungs. To date, treatment benefit has exceeded 12Â months without dose-limiting toxicities or related serious adverse events and with documented radiologic stabilization and improved performance status
Prospectus, April 15, 2009
https://spark.parkland.edu/prospectus_2009/1011/thumbnail.jp
Recommended from our members
Fluorescent humanized anti-CEA antibody specifically labels metastatic pancreatic cancer in a patient-derived orthotopic xenograft (PDOX) mouse model.
Pancreatic cancer is a highly lethal disease in part due to incomplete tumor resection. Targeting by tumor-specific antibodies conjugated with a fluorescent label can result in selective labeling of cancer in vivo for surgical navigation. In the present study, we describe a patient-derived orthotopic xenograft model of pancreatic cancer that recapitulated the disease on a gross and microscopic level, along with physiologic clinical manifestations. We additionally show that the use of an anti-CEA antibody conjugated to the near-infrared (NIR) fluorescent dye, IRDye800CW, can selectively highlight the pancreatic cancer and its metastases in this model with a tumor-to-background ratio of 3.5 (SEM 0.9). The present results demonstrate the clinical potential of this labeling technique for fluorescence-guided surgery of pancreatic cancer
Prospectus, July 1, 2009
https://spark.parkland.edu/prospectus_2009/1017/thumbnail.jp
Prospectus, April 29, 2009
https://spark.parkland.edu/prospectus_2009/1013/thumbnail.jp
Prospectus, March 4, 2009
https://spark.parkland.edu/prospectus_2009/1006/thumbnail.jp
Prospectus, March 18, 2009
https://spark.parkland.edu/prospectus_2009/1008/thumbnail.jp
Prospectus, February 18, 2009
https://spark.parkland.edu/prospectus_2009/1004/thumbnail.jp
Prospectus, May 6, 2009
https://spark.parkland.edu/prospectus_2009/1014/thumbnail.jp
- …